Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2026 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
GlaxoSmithKline and Pfizer have created a joint research and development company with the goal of creating new anti-HIV medications more quickly and efficiently than either company could on its own. The joint company has four anti-HIV drugs in Phase II clinical trials. --------------------- Bristol-Myers Squibb has announced it has created new copayment assistance programs for its medications Reyataz, Sustiva, and Atripla. The programs help people with private insurance who spend more than $50 in copays for the drugs, covering up to $200 per month. --------------------- Although current guidelines state Sustiva shouldn't be taken by pregnant women because of a risk of birth defects, data from a 17-year study reported in the journal AIDS has shown that birth-defect rates among infants born to women taking the drug were similar to rates among those born to women taking other anti-HIV drugs or taking no antiretrovirals.. --------------------- Interim data from a study of Kaletra and Isentress have shown that dual therapy with the two medications produces a faster decline in viral loads than a standard three-drug regimen. CD4-cell increases were similar through both treatment approaches. --------------------- A study presented at the 15th British HIV Association Meeting has shown that suboptimal adherence may be less hazardous with Prezista than with other protease inhibitors. About 76% of study subjects with suboptimal adherence on Prezista achieved undetectable HIV levels, compared to 53% of those with suboptimal adherence to another PI. --------------------- The Food and Drug Administration has ordered changes to the label of Kaletra to warn that it may raise the risk for heart rhythm abnormalities. The new label says Kaletra should be used with caution in patients with underlying heart disease or preexisting cardiac problems. --------------------- Research reported at the 10th International Workshop on Clinical Pharmacology of HIV Therapy has shown that Isentress reaches high concentrations in the genital tract, suggesting that the drug may be useful as preexposure prophylaxis to prevent transmission of HIV through heterosexual intercourse. --------------------- Data from a four-year study reported in the journal AIDS Research and Human Retroviruses has shown that Aquamid, a polyacrylamine hydrogel filler, is a safe and effective treatment for HIV-related facial wasting. Nearly 90% of the HIVers treated with Aquamid reported being 'very satisfied' or 'satisfied.' --------------------- Gilead Sciences has launched a Phase II clinical trial of its four-drug combination pill Quad, which contains Emtriva, Viread, the experimental integrase inhibitor elvitegravir, and a boosting agent known as GS9350. The study includes 75 treatment-naive HIVers at 50 U.S. sites. --------------------- Apricitabine, a new nucleoside analog in development by Avexa, was shown in human studies to be effective in suppressing viral loads with a minimal effect on blood lipids, no recorded resistance, and few adverse side effects after 96 weeks of treatment. --------------------- Tobira Therapeutics has launched a Phase IIa clinical trial of its experimental CCR5 antagonist TAK-652 that includes 40 treatment-experienced HIVers in the United States and Argentina. --------------------- Irreversible pepsin fraction, an experimental compound developed by Immunotech Laboratories, has been shown in lab tests to bind to and disable a key protein HIV uses to attach to and infect immune system cells. Human studies are planned. --------------------- Researchers have captured on video the direct transfer of HIV between immune system cells through bridge-like connections called virological synapses. It was thought that HIV spread only through free-roaming viral particles that attached to and infected the cells. The researchers hope their findings lead to new methods to block such transmissions. --------------------- A study in the Journal of Clinical Endocrinology and Metabolism has shown that the hormone leptin, produced by fat cells, can improve symptoms of HIV-related lipodystrophy, including lowering cholesterol and triglycerides in the blood, reducing abdominal fat, and improving insulin resistance. --------------------- A test developed by researchers at Imperial College London and the International AIDS Vaccine Initiative may help weed out ineffective HIV vaccine candidates. The test combines live HIV with blood samples from candidates inoculated with experimental vaccines to quickly determine whether the shots keep the virus from replicating. --------------------- The Food and Drug Administration has approved the use of PegIntron and Rebetol for second-line treatment of hepatitis C among patients who did not achieve a sustained response to first-line treatment. The combination is the first therapy approved for treatment-experienced individuals.
From our Sponsors
Most Popular
The road to U=U: How science has been liberating HIV+ people for a decade
July 01 2026 12:05 PM
How to find an HIV-competent healthcare provider, according to advocates
May 19 2026 4:55 PM
Plus: Featured Video
Latest Stories
A New Once-Daily Pill to Treat HIV Just Got the FDA’s Green Light
August 31 2026 2:31 PM
Why affirming faith communities belong in the fight to end HIV
August 30 2026 8:00 AM
Navigating a new HIV diagnosis? Advocates say community is key
August 25 2026 3:33 PM
Gay Wine Weekend toasts 15 years of raising funds for HIV
August 25 2026 11:00 AM
A new HIV diagnosis doesn't have to be nerve-wracking. Advocates share their advice
July 30 2026 12:01 PM
Zero HIV Stigma Day: The epidemic we still choose to ignore
July 21 2026 7:00 AM
National HIV Prevention Day: Awareness is my superpower
July 17 2026 8:00 AM
Federal court clarifies that people with HIV can join the military again
June 03 2026 5:36 PM
Can a single infusion of immune cells suppress HIV for years?
May 11 2026 11:39 AM
Newly diagnosed with HIV? Advocates share their best advice for seeking treatment
April 29 2026 3:32 PM
National HIV advocacy group's CEO rejects claims of crisis
April 21 2026 5:14 PM
Beyond awareness: How youth leadership is reshaping the HIV response
April 10 2026 9:12 AM
Saving public health? AIDS United's new CEO has a plan
March 23 2026 9:48 AM
Struggling with daily HIV meds? Monthly shots may be the answer
March 20 2026 7:12 AM
Trending stories
Recommended Stories for You
































































